Cover Image
市場調查報告書

CureVac GmbH:產品平台分析

CureVac GmbH - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 253771
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
CureVac GmbH:產品平台分析 CureVac GmbH - Product Pipeline Review - 2016
出版日期: 2016年04月20日 內容資訊: 英文 49 Pages
簡介

CureVac GmbH 是設計、開發、製造腫瘤及感染性疾病的治療和預防疫苗的傳訊RNA (mRNA) 分子的生物製藥公司。該公司研究開發前列腺癌,狂犬病(恐水症),流感等治療藥。

本報告提供CureVac GmbH 的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

CureVac GmbH的基本資料

  • CureVac GmbH概要
  • 主要資訊
  • 企業資料

CureVac GmbH:R&D概要

  • 主要的治療範圍

CureVac GmbH:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

CureVac GmbH:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

CureVac GmbH:藥物簡介

  • CV-9104
  • CV-9103
  • CV-9201
  • CV-8102
  • nadorameran
  • 腫瘤用寡核苷酸Cancer
  • 感染疾病用寡核苷酸
  • 流感病毒感染用寡核苷酸
  • 呼吸道融合病毒(RSV)疫苗用寡核苷酸
  • 感染疾病用疫苗
  • HIV用寡核苷酸
  • 呼吸道融合病毒(RSV)-1感染疾病用寡核苷酸
  • 輪狀病毒感染疾病用寡核苷酸
  • 未公佈的症狀用寡核苷酸
  • 腫瘤學用疫苗1
  • 腫瘤學用疫苗

CureVac GmbH:開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型

CureVac GmbH:最近的開發平台趨勢

CureVac GmbH:暫停中的計劃

CureVac GmbH:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08025CDB

Summary

Global Markets Direct's, 'CureVac GmbH - Product Pipeline Review - 2016', provides an overview of the CureVac GmbH's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CureVac GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of CureVac GmbH
  • The report provides overview of CureVac GmbH including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses CureVac GmbH's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features CureVac GmbH's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate CureVac GmbH's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for CureVac GmbH
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding CureVac GmbH's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CureVac GmbH Snapshot
    • CureVac GmbH Overview
    • Key Information
    • Key Facts
  • CureVac GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • CureVac GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • CureVac GmbH - Pipeline Products Glance
    • CureVac GmbH - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • CureVac GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • CureVac GmbH - Drug Profiles
    • CV-9104
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CV-9103
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CV-9201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CV-8102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nadorameran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide for Infectious Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide for Influenza Virus Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide for respiratory syncytial virus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • infectious disease vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide for HIV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide for Respiratory Syncytial Virus-1 Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide for Rotavirus Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotides for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine 1 for oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CureVac GmbH - Pipeline Analysis
    • CureVac GmbH - Pipeline Products by Target
    • CureVac GmbH - Pipeline Products by Route of Administration
    • CureVac GmbH - Pipeline Products by Molecule Type
  • CureVac GmbH - Recent Pipeline Updates
  • CureVac GmbH - Dormant Projects
  • CureVac GmbH - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CureVac GmbH, Key Information
  • CureVac GmbH, Key Facts
  • CureVac GmbH - Pipeline by Indication, 2016
  • CureVac GmbH - Pipeline by Stage of Development, 2016
  • CureVac GmbH - Monotherapy Products in Pipeline, 2016
  • CureVac GmbH - Partnered Products in Pipeline, 2016
  • CureVac GmbH - Partnered Products/ Combination Treatment Modalities, 2016
  • CureVac GmbH - Out-Licensed Products in Pipeline, 2016
  • CureVac GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • CureVac GmbH - Phase II, 2016
  • CureVac GmbH - Phase I, 2016
  • CureVac GmbH - Preclinical, 2016
  • CureVac GmbH - Discovery, 2016
  • CureVac GmbH - Pipeline by Target, 2016
  • CureVac GmbH - Pipeline by Route of Administration, 2016
  • CureVac GmbH - Pipeline by Molecule Type, 2016
  • CureVac GmbH - Recent Pipeline Updates, 2016
  • CureVac GmbH - Dormant Developmental Projects,2016
  • CureVac GmbH, Other Locations

List of Figures

  • CureVac GmbH - Pipeline by Top 10 Indication, 2016
  • CureVac GmbH - Pipeline by Stage of Development, 2016
  • CureVac GmbH - Monotherapy Products in Pipeline, 2016
  • CureVac GmbH - Out-Licensed Products in Pipeline, 2016
  • CureVac GmbH - Pipeline by Top 10 Target, 2016
  • CureVac GmbH - Pipeline by Route of Administration, 2016
  • CureVac GmbH - Pipeline by Molecule Type, 2016
Back to Top